Navigation Links
Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis

tional-hazards analysis.

This news release contains forward-looking statements regarding eprodisate (KIACTA(TM)), as well as regarding continuing and further development efforts. These statements are based on the current analysis and expectations of management. Drug development necessarily involves numerous risks and uncertainties, which could cause actual results to differ materially from this current analysis and these expectations. Analysis regarding the results of clinical trials may not provide definitive results regarding safety, tolerability or therapeutic benefits. There is no certainty that regulators will ultimately approve eprodisate (KIACTA(TM)) for sale to the public. Risks and uncertainties may include: failure to demonstrate the safety, tolerability and efficacy of our product, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, the expense and uncertainty of obtaining regulatory approval, including from the FDA, and the possibility of having to conduct additional clinical trials. Further, even if regulatory approval is obtained, therapeutic products are generally subject to: stringent on-going governmental regulation, challenges in gaining market acceptance, and competition. Neither Neurochem Inc., nor Neurochem (International) Limited undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise. Please see Neurochem Inc.'s Annual Information Form for further risk factors that might affect Neurochem Inc., Neurochem (International) Limited and their respective businesses.

    For further information, please contact:


    Lise Hebert, PhD                        (450) 680-4572

    Vice President, Corporate

    Communications                          

lhebert@neurochem.com

CONTACT: Lise Hebert, PhD, Vice President,
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
2. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
3. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
4. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
5. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
6. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
9. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
11. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
Post Your Comments:
(Date:8/28/2015)... and ATLANTA , August 28, ... US Food and Drug Administration (FDA) cleared the MagVita TMS ... adult patients who have failed to receive satisfactory improvement from ... non-invasive technique for stimulating neural tissue in the part of ... The procedure has been proven safe and effective and MagVenture ...
(Date:8/28/2015)... , Aug. 28, 2015 , ... Dr. Ra from Biostar , Published in ,Stem ... increase of lifespan through multiple IV administration of Adipose-derived ... and life expectancy found , Commercialization within 5 ... determined the possibility that adult mesenchymal stem cells (MSCs) ...
(Date:8/28/2015)... LONDRES, 28 de agosto de 2015   ... su participación en el  Congreso de la ESC ... más recientes y novedosas, entre ellas HeartModel A.I. ... las personas y la tecnología con los protocolos ... guiar los tratamientos y permitir atención en el ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
... Asthma Medication Linked to Respiratory Improvement in NYC ... ... corticosteroids (ICS),antiinflammatory treatments often prescribed for asthma, may be beneficial,in preventing ... 2007, the 73rd annual international scientific assembly,of the American College of ...
... 24 Pharmasset, Inc.,(Nasdaq: VRUS ) has ... and,Drug Administration (FDA) for R7128 for the treatment ... a prodrug of PSI-6130, an oral cytidine,nucleoside analog ... Pharmasset,s collaboration with Roche. Pharmasset is currently,enrolling a ...
Cached Medicine Technology:Inhaled Steriods Used as Preventive Treatment Post 9/11 2Inhaled Steriods Used as Preventive Treatment Post 9/11 3R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection 2R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection 3R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection 4R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection 5
(Date:8/28/2015)... ... 28, 2015 , ... The Nashville Business Journal recently announced ... business. Mr. Troy Mizell, Chairman of the Board at MyGenetx, is one ... Veterans Awards will recognize Nashville military veterans who, through their professional and personal ...
(Date:8/28/2015)... CA (PRWEB) , ... August 28, 2015 , ... ... price on Zoom teeth whitening. For just $199, patients can currently receive a one ... traditional in-office teeth whitening procedures, but it includes a number of unique features that ...
(Date:8/28/2015)... ... August 28, 2015 , ... The newest therapy to ... available for general use any time soon, according to educational website Surviving Mesothelioma. ... that received orphan drug designation for mesothelioma last week from the FDA, will now ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... now consolidated as MDL 2545, Testosterone Replacement Therapy Products Liability Litigation, are in ... number of custodial files the PSC may receive for corporate employees involved in ...
(Date:8/28/2015)... ... 28, 2015 , ... An independent study recently conducted confirms ... of change to treatment recommendations and diagnosis. The 2015 return on investment (ROI) ... and analyzed WorldCare’s second opinion process. , The study reviewed cases across three ...
Breaking Medicine News(10 mins):Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 4Health News:WorldCare International, Inc. Celebrates Findings of Independent ROI Study 2
... , ... poll, Supporting Iraq and Afghanistan Troops and Veterans, found two out of three Americans know ... and Afghanistan veterans and troops face. , ... Washington, DC (Vocus) May 10, 2010 -- A new public awareness poll, ...
... French . , Neurological research and clinical ... London and McGill University of Montreal entered an agreement ... field. Sir Keith O,Nions, Rector of Imperial, and Heather ... to sign the partnership documents, which will consolidate existing ...
... ... ... Clyburn will give the commencement address at the 135th Commencement ceremony for Meharry Medical College ... University in the Allen Arena. Doors open at 11:30 a.m., , , , ,Congressman Clyburn is ...
... show need for treatment even when pulmonary disease looks ... News) -- Worsening of chronic obstructive pulmonary disease (COPD) ... stroke, a new study finds. , British researchers looked ... in 426 patients and 633 ischemic strokes (blockage of ...
... help University of Central Florida researchers explore new ways ... and other neurological disorders. Stephen Lambert, an associate ... of UCF,s Hybrid Systems Laboratory, has received $428,000, the ... team will study the breakdown of myelin, a substance ...
... dyslexia often struggle with reading, writing, and spelling, despite ... other areas. New neurological research has found that these ... structural differences within an important information highway in the ... The findings are published in the June 2010 issue ...
Cached Medicine News:Health News:New Poll Finds Majority of Americans Are Unaware of Issues Facing Iraq/Afghanistan Veterans and Troops 2Health News:New Poll Finds Majority of Americans Are Unaware of Issues Facing Iraq/Afghanistan Veterans and Troops 3Health News:Trans-Atlantic agreement a boost to neuroscience research 2Health News:Congressman James E. Clyburn to Give Meharry Medical College Commencement Address 2Health News:Congressman James E. Clyburn to Give Meharry Medical College Commencement Address 3Health News:$1.9 million grant to help UCF find multiple sclerosis 'nerve-ana' 2Health News:Differences in language circuits in the brain linked to dyslexia 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: